These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 28694687)

  • 21. Results of a Multicenter, Randomized, Double-Masked, Placebo-Controlled Clinical Study of the Efficacy and Safety of Visomitin Eye Drops in Patients with Dry Eye Syndrome.
    Brzheskiy VV; Efimova EL; Vorontsova TN; Alekseev VN; Gusarevich OG; Shaidurova KN; Ryabtseva AA; Andryukhina OM; Kamenskikh TG; Sumarokova ES; Miljudin ES; Egorov EA; Lebedev OI; Surov AV; Korol AR; Nasinnyk IO; Bezditko PA; Muzhychuk OP; Vygodin VA; Yani EV; Savchenko AY; Karger EM; Fedorkin ON; Mironov AN; Ostapenko V; Popeko NA; Skulachev VP; Skulachev MV
    Adv Ther; 2015 Dec; 32(12):1263-79. PubMed ID: 26660938
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of retinol palmitate as a treatment for dry eye: a cytological evaluation.
    Kobayashi TK; Tsubota K; Takamura E; Sawa M; Ohashi Y; Usui M
    Ophthalmologica; 1997; 211(6):358-61. PubMed ID: 9380354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diquafosol ophthalmic solution 3 %: a review of its use in dry eye.
    Keating GM
    Drugs; 2015 May; 75(8):911-22. PubMed ID: 25968930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SkQ1 Ophthalmic Solution for Dry Eye Treatment: Results of a Phase 2 Safety and Efficacy Clinical Study in the Environment and During Challenge in the Controlled Adverse Environment Model.
    Petrov A; Perekhvatova N; Skulachev M; Stein L; Ousler G
    Adv Ther; 2016 Jan; 33(1):96-115. PubMed ID: 26733410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and relevant factors of 2% rebamipide ophthalmic suspension treatment in dry eye.
    Ueda K; Matsumiya W; Otsuka K; Maeda Y; Nagai T; Nakamura M
    BMC Ophthalmol; 2015 Jun; 15():58. PubMed ID: 26048396
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trehalose eye drops in the treatment of dry eye syndrome.
    Matsuo T; Tsuchida Y; Morimoto N
    Ophthalmology; 2002 Nov; 109(11):2024-9. PubMed ID: 12414409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group.
    Stevenson D; Tauber J; Reis BL
    Ophthalmology; 2000 May; 107(5):967-74. PubMed ID: 10811092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A multicenter, randomized, double-masked, placebo-controlled trial of compound wild chrysanthemum eye masks for mild and moderate dry eye].
    Wu JL; Liu ZG; Jin M; Liu J; Li Y; Bi HS; Xie XF; Zhang ML; Shi HJ; Gao XM; Li L; Huang CH
    Zhonghua Yan Ke Za Zhi; 2021 Aug; 57(8):601-607. PubMed ID: 34344121
    [No Abstract]   [Full Text] [Related]  

  • 29. Long-term results of treatment with diquafosol ophthalmic solution for aqueous-deficient dry eye.
    Koh S; Ikeda C; Takai Y; Watanabe H; Maeda N; Nishida K
    Jpn J Ophthalmol; 2013 Sep; 57(5):440-6. PubMed ID: 23740285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic effects of 3% diquafosol ophthalmic solution in patients with short tear film break-up time-type dry eye disease.
    Mun Y; Kwon JW; Oh JY
    BMC Ophthalmol; 2018 Sep; 18(1):237. PubMed ID: 30185156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.
    Sall K; Stevenson OD; Mundorf TK; Reis BL
    Ophthalmology; 2000 Apr; 107(4):631-9. PubMed ID: 10768324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TNF-α inhibitor tanfanercept (HBM9036) improves signs and symptoms of dry eye in a phase 2 trial in the controlled adverse environment in China.
    Dong Y; Wang S; Cong L; Zhang T; Cheng J; Yang N; Qu X; Li D; Zhou X; Wang H; Lee M; Wang M; Chen S; Ousler GW; Chen X; Xie L
    Int Ophthalmol; 2022 Aug; 42(8):2459-2472. PubMed ID: 35192105
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vitamin A Palmitate and Carbomer Gel Protects the Conjunctiva of Patients With Long-term Prostaglandin Analogs Application.
    Cui X; Xiang J; Zhu W; Wei A; Le Q; Xu J; Zhou X
    J Glaucoma; 2016 Jun; 25(6):487-92. PubMed ID: 26317483
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of sodium hyaluronate and carboxymethylcellulose in treating mild to moderate dry eye disease.
    Lee JH; Ahn HS; Kim EK; Kim TI
    Cornea; 2011 Feb; 30(2):175-9. PubMed ID: 21045674
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of an enhanced viscosity artificial tear for moderate to severe dry eye disease: A multicenter, double-masked, randomized 30-day study.
    Lievens C; Berdy G; Douglass D; Montaquila S; Lin H; Simmons P; Carlisle-Wilcox C; Vehige J; Haque S
    Cont Lens Anterior Eye; 2019 Aug; 42(4):443-449. PubMed ID: 30573298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial.
    Chen M; Gong L; Sun X; Xie H; Zhang Y; Zou L; Qu J; Li Y; He J
    J Ocul Pharmacol Ther; 2010 Aug; 26(4):361-6. PubMed ID: 20698799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial.
    Amparo F; Dastjerdi MH; Okanobo A; Ferrari G; Smaga L; Hamrah P; Jurkunas U; Schaumberg DA; Dana R
    JAMA Ophthalmol; 2013 Jun; 131(6):715-723. PubMed ID: 23599118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Efficacy of a recombinant bovine basic fibroblast growth factor gel for the treatment of moderate dry eye: a multicenter randomized double-blind parallel controlled clinical trial].
    Huang CH; Liu ZG; Zhang MC; Sun XG; Xu JJ; Liang LY; Lin X; Wang JS; Tian L; Wu SQ; Liu Y; Zhong TL
    Zhonghua Yan Ke Za Zhi; 2021 Dec; 57(12):930-938. PubMed ID: 34865452
    [No Abstract]   [Full Text] [Related]  

  • 39. Efficacy and Safety of the Melanocortin Pan-Agonist PL9643 in a Phase 2 Study of Patients with Dry Eye Disease.
    Evans D; Kenyon K; Ousler G; Watson M; Vollmer P; McLaurin EB; Torkildsen G; Winters J; Dodd J; Jordan R; Wills ST; Spana C
    J Ocul Pharmacol Ther; 2023 Nov; 39(9):600-610. PubMed ID: 37677000
    [No Abstract]   [Full Text] [Related]  

  • 40. Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial.
    Avni I; Garzozi HJ; Barequet IS; Segev F; Varssano D; Sartani G; Chetrit N; Bakshi E; Zadok D; Tomkins O; Litvin G; Jacobson KA; Fishman S; Harpaz Z; Farbstein M; Yehuda SB; Silverman MH; Kerns WD; Bristol DR; Cohn I; Fishman P
    Ophthalmology; 2010 Jul; 117(7):1287-93. PubMed ID: 20304499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.